Optical and radioiodinated tethered Hsp90 inhibitors reveal selective internalization of ectopic Hsp90 in malignant breast tumor cells

Chemistry and Biology

Volumn 20, Issue 9, 2013, Pages 1187-1197

  Barrott, Jared J ^a   Hughes, Philip F ^a   Osada, Takuya ^a   Yang, Xiao Yi ^a   Hartman, Zachary C ^a   Loiselle, David R ^a   Spector, Neil L ^a   Neckers, Len ^c   Rajaram, Narasimhan ^b   Hu, Fangyao ^b   Ramanujam, Nimmi ^b   Vaidyanathan, Ganesan ^a   Zalutsky, Michael R ^a   Lyerly, H Kim ^a   Haystead, Timothy A ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Duke University   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; HEAT SHOCK PROTEIN 90 INHIBITOR; MACROGOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST TUMOR; CELL MEMBRANE; CONTROLLED STUDY; DRUG BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; FLUOR; INTERNALIZATION; MOLECULAR PROBE; MOUSE; NONHUMAN; OPTICS; PRIORITY JOURNAL; RADIOIODINATION; TUMOR CELL;

MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HALOGENATION; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IODINE RADIOISOTOPES; ISOTOPE LABELING; MCF-7 CELLS; MICE; MICE, SCID; TRANSPLANTATION, HETEROLOGOUS;

EID: 84884534310     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2013.08.004     Document Type: Article

References (47)

1. J.J. Barrott, and T.A. Haystead Hsp90, an unlikely ally in the war on cancer FEBS J. 280 2013 1381 1396
2. J.Q. Brown, L.G. Wilke, J. Geradts, S.A. Kennedy, G.M. Palmer, and N. Ramanujam Quantitative optical spectroscopy: a robust tool for direct measurement of breast cancer vascular oxygenation and total hemoglobin content in vivo Cancer Res. 69 2009 2919 2926
3. C.F. Cheng, J. Fan, M. Fedesco, S. Guan, Y. Li, B. Bandyopadhyay, A.M. Bright, D. Yerushalmi, M. Liang, and M. Chen Transforming growth factor alpha (TGFalpha)-stimulated secretion of HSP90alpha: using the receptor LRP-1/CD91 to promote human skin cell migration against a TGFbeta-rich environment during wound healing Mol. Cell. Biol. 28 2008 3344 3358
4. Q. Cheng, J.T. Chang, J. Geradts, L.M. Neckers, T. Haystead, N.L. Spector, and H.K. Lyerly Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer Breast Cancer Res. 14 2012 R62
5. G. Chiosis, B. Lucas, H. Huezo, D. Solit, A. Basso, and N. Rosen Development of purine-scaffold small molecule inhibitors of Hsp90 Curr. Cancer Drug Targets 3 2003 371 376
6. P. Csermely, T. Schnaider, C. Soti, Z. Prohászka, and G. Nardai The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review Pharmacol. Ther. 79 1998 129 168
7. P.C. Echeverría, A. Bernthaler, P. Dupuis, B. Mayer, and D. Picard An interaction network predicted from public data as a discovery tool: application to the Hsp90 molecular chaperone machine PLoS ONE 6 2011 e26044
8. L. Esserman, Y. Shieh, and I. Thompson Rethinking screening for breast cancer and prostate cancer JAMA 302 2009 1685 1692
9. B.K. Eustace, T. Sakurai, J.K. Stewart, D. Yimlamai, C. Unger, C. Zehetmeier, B. Lain, C. Torella, S.W. Henning, and G. Beste Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness Nat. Cell Biol. 6 2004 507 514
10. P. Fadden, K.H. Huang, J.M. Veal, P.M. Steed, A.F. Barabasz, B. Foley, M. Hu, J.M. Partridge, J. Rice, and A. Scott Application of chemoproteomics to drug discovery: identification of a clinical candidate targeting hsp90 Chem. Biol. 17 2010 686 694
11. M. Gerlinger, A.J. Rowan, S. Horswell, J. Larkin, D. Endesfelder, E. Gronroos, P. Martinez, N. Matthews, A. Stewart, and P. Tarpey Intratumor heterogeneity and branched evolution revealed by multiregion sequencing N. Engl. J. Med. 366 2012 883 892
12. J.P. Grenert, W.P. Sullivan, P. Fadden, T.A. Haystead, J. Clark, E. Mimnaugh, H. Krutzsch, H.J. Ochel, T.W. Schulte, and E. Sausville The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation J. Biol. Chem. 272 1997 23843 23850
13. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
14. P.F. Hughes, J.J. Barrott, D.A. Carlson, D.R. Loiselle, B.L. Speer, K. Bodoor, L.A. Rund, and T.A. Haystead A highly selective Hsp90 affinity chromatography resin with a cleavable linker Bioorg. Med. Chem. 20 2012 3298 3305
15. M. Ide, and Y. Suzuki Is whole-body FDG-PET valuable for health screening? For Eur. J. Nucl. Med. Mol. Imaging 32 2005 339 341
16. A. Kamal, L. Thao, J. Sensintaffar, L. Zhang, M.F. Boehm, L.C. Fritz, and F.J. Burrows A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors Nature 425 2003 407 410
17. Y.S. Kim, S.V. Alarcon, S. Lee, M.J. Lee, G. Giaccone, L. Neckers, and J.B. Trepel Update on Hsp90 inhibitors in clinical trial Curr. Top. Med. Chem. 9 2009 1479 1492
18. F. Koga, K. Kihara, and L. Neckers Inhibition of cancer invasion and metastasis by targeting the molecular chaperone heat-shock protein 90 Anticancer Res. 29 2009 797 807
19. C. Liu, N. Rajaram, K. Vishwanath, T. Jiang, G.M. Palmer, and N. Ramanujam Experimental validation of an inverse fluorescence Monte Carlo model to extract concentrations of metabolically relevant fluorophores from turbid phantoms and a murine tumor model J. Biomed. Opt. 17 2012 077012
20. J. McCready, J.D. Sims, D. Chan, and D.G. Jay Secretion of extracellular hsp90alpha via exosomes increases cancer cell motility: a role for plasminogen activation BMC Cancer 10 2010 294
21. M. Mollapour, and L. Neckers Post-translational modifications of Hsp90 and their contributions to chaperone regulation Biochim. Biophys. Acta 1823 2012 648 655
22. K. Moulick, J.H. Ahn, H. Zong, A. Rodina, L. Cerchietti, E.M. Gomes DaGama, E. Caldas-Lopes, K. Beebe, F. Perna, and K. Hatzi Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90 Nat. Chem. Biol. 7 2011 818 826
23. L. Neckers, and P. Workman Hsp90 molecular chaperone inhibitors: are we there yet? Clin. Cancer Res. 18 2012 64 76
24. L. Neckers, M. Mollapour, and S. Tsutsumi The complex dance of the molecular chaperone Hsp90 Trends Biochem. Sci. 34 2009 223 226
25. R.M. Neve, K. Chin, J. Fridlyand, J. Yeh, F.L. Baehner, T. Fevr, L. Clark, N. Bayani, J.P. Coppe, and F. Tong A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes Cancer Cell 10 2006 515 527
26. G.M. Palmer, and N. Ramanujam Monte-Carlo-based model for the extraction of intrinsic fluorescence from turbid media J. Biomed. Opt. 13 2008 024017
27. G.M. Palmer, R.J. Boruta, B.L. Viglianti, L. Lan, I. Spasojevic, and M.W. Dewhirst Non-invasive monitoring of intra-tumor drug concentration and therapeutic response using optical spectroscopy J. Control. Release 142 2010 457 464
28. E. Pick, Y. Kluger, J.M. Giltnane, C. Moeder, R.L. Camp, D.L. Rimm, and H.M. Kluger High HSP90 expression is associated with decreased survival in breast cancer Cancer Res. 67 2007 2932 2937
29. R. Ray, and T.A. Haystead Phosphoproteome analysis in yeast Methods Enzymol. 366 2003 95 103
30. R.S. Samant, P.A. Clarke, and P. Workman The expanding proteome of the molecular chaperone HSP90 Cell Cycle 11 2012 1301 1308
31. H. Schoder, and M. Gonen Screening for cancer with PET and PET/CT: potential and limitations J. Nucl. Med. 48 Suppl 1 2007 4S 18S
32. K. Sidera, A. El Hamidieh, A. Mamalaki, and E. Patsavoudi The 4C5 cell-impermeable anti-HSP90 antibody with anti-cancer activity, is composed of a single light chain dimer PLoS ONE 6 2011 e23906
33. J.D. Sims, J. McCready, and D.G. Jay Extracellular heat shock protein (Hsp)70 and Hsp90α assist in matrix metalloproteinase-2 activation and breast cancer cell migration and invasion PLoS ONE 6 2011 e18848
34. R.A. Smith, V. Cokkinides, D. Brooks, D. Saslow, and O.W. Brawley Cancer screening in the United States, 2010: a review of current American Cancer Society guidelines and issues in cancer screening CA Cancer J. Clin. 60 2010 99 119
35. D. Stellas, A. El Hamidieh, and E. Patsavoudi Monoclonal antibody 4C5 prevents activation of MMP2 and MMP9 by disrupting their interaction with extracellular HSP90 and inhibits formation of metastatic breast cancer cell deposits BMC Cell Biol. 11 2010 51
36. J. Trepel, M. Mollapour, G. Giaccone, and L. Neckers Targeting the dynamic HSP90 complex in cancer Nat. Rev. Cancer 10 2010 537 549
37. S. Tsutsumi, and L. Neckers Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis Cancer Sci. 98 2007 1536 1539
38. S. Tsutsumi, B. Scroggins, F. Koga, M.J. Lee, J. Trepel, S. Felts, C. Carreras, and L. Neckers A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasion Oncogene 27 2008 2478 2487
39. S. Tsutsumi, M. Mollapour, C. Graf, C.T. Lee, B.T. Scroggins, W. Xu, L. Haslerova, M. Hessling, A.A. Konstantinova, and J.B. Trepel Hsp90 charged-linker truncation reverses the functional consequences of weakened hydrophobic contacts in the N domain Nat. Struct. Mol. Biol. 16 2009 1141 1147
40. C.K. Vaughan, L. Neckers, and P.W. Piper Understanding of the Hsp90 molecular chaperone reaches new heights Nat. Struct. Mol. Biol. 17 2010 1400 1404
41. X. Wang, X. Song, W. Zhuo, Y. Fu, H. Shi, Y. Liang, M. Tong, G. Chang, and Y. Luo The regulatory mechanism of Hsp90alpha secretion and its function in tumor malignancy Proc. Natl. Acad. Sci. USA 106 2009 21288 21293
42. Y. Wang, J.B. Trepel, L.M. Neckers, and G. Giaccone STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer Curr. Opin. Investig. Drugs 11 2010 1466 1476
43. K. Warning, M.G. Hildebrandt, B. Kristensen, and M. Ewertz Utility of 18FDG-PET/CT in breast cancer diagnostics - a systematic review Dan. Med. Bull. 58 2011 A4289
44. L. Whitesell, and S.L. Lindquist HSP90 and the chaperoning of cancer Nat. Rev. Cancer 5 2005 761 772
45. W. Xu, X. Yuan, Z. Xiang, E. Mimnaugh, M. Marcu, and L. Neckers Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex Nat. Struct. Mol. Biol. 12 2005 120 126
46. X. Yin, H. Zhang, K. Lundgren, L. Wilson, F. Burrows, and C.G. Shores BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy Int. J. Cancer 126 2010 1216 1225
47. D. Zhou, T.F. Liu, Y. Ye, J. Ying, W. Shin, L. Ogawa, T. Inoue, W. Lee, A. Adjiri-Awere, and L. Kolodzieyski Associating retinal drug exposure and retention with the ocular toxicity profiles of Hsp90 inhibitors J. Clin. Oncol. 2012 30 (suppl; abstr 3086)